Atorvia Health Technologies

Atorvia is a private Canadian pre-clinical biotechnology company developing targeted therapeutics for organ failure, initially focused on kidney disease. The company uses functional proteomics and machine learning to identify biological drivers of organ dysfunction and engineer kidney-targeted therapies. Its lead program is a peptide therapeutic intended to prevent regulated cell death and treat acute kidney injury, an area with high unmet need and no effective approved therapy. Atorvia positions itself as building a broader renal and organ-failure franchise, with early programs aimed at preventing and treating kidney failure and related severe complications.